Company Information
Industry 制造业
Company Introduction 广誉远始创于明嘉靖二十年(公元1541年),距今已有近500年的历史,其间历经广盛号药店、广升聚、广升蔚、广升誉、广升远、山西中药厂、山西广誉远等十几个商号药厂更迭。在清代曾与广州陈李济(1600年创建)、北京同仁堂(1669年创建)、杭州胡庆余堂(1874年创建)并称为“四大药店”,现为山西省中药企业典范,并在2006年成为首批被中华人民共和国商务部认定的“中华老字号”企业。 “尊德贵生,传承创新”是广誉远的企业理念,广誉远坚定地以文化为先导,专注于中医药领域,坚持“继承与创新”的发展策略,充分利用企业内部的产品资源,通过持续的品牌建设和创新营销,努力实现高品质中药的企业目标。 广誉远主导产品“龟龄集”和“定坤丹”,是中华中医药宝库珍藏的养生至宝,是博大精深的中医药文化的智慧结晶,现为国家级保密处方,分别在2008年和2011年被中华人民共和国国务院评为国家级非物质文化遗产。龟龄集、定坤丹宫廷出身,数百年的药用历史,深刻佐证了其功效;多位皇帝的相关御批,真实确凿的史料档案,更显其品味尊贵。包括龟龄集、定坤丹在内,广誉远系列产品荣获众多国际级奖项、国家级荣誉,在国际传统医药界有深远影响。 近500年来,广誉远严苛制药,精益求精,秉承“修合虽无人见,存心自有天知”的古训,遵循“非义而为,一介不取;合情之道,九百何辞”的准则,恪守诚信自律的晋商精神,以信誉为根本,“以义制利”铸就了百年老店的历久弥新。
Main Business 高科技生物制药
Legal Representative 李晓军
Top Executives
董事长:李晓军
董事:季占璐,刘兆维
独立董事:王继军,李先荣,赵选民
Top 5 Shareholder
Shareholder name Nature Holding Date
晋创投资有限公司流通A股14.61%30/09/2024
蒋仕波流通A股1.67%30/09/2024
招商银行股份有限公司-南方中证1000交易型开放式指数证券投资基金流通A股1.16%30/09/2024
香港中央结算有限公司流通A股1.04%30/09/2024
西安东盛集团有限公司流通A股0.90%30/09/2024
Company Secretary 唐云
Solicitors 北京市海润律师事务所
Auditors 利安达会计师事务所(特殊普通合伙)
Tel No 0351-7099061
Fax No 0351-7099130
Website www.guangyuyuan.com
Email irm@guangyuyuan.com.cn
Company Address
Register: 山西省晋中市太谷区广誉远路1号
Office: 山西省太原市小店区长风街129号山西梧桐大厦26层
Listing Date 05/11/1996
Shares Capital
Shares Capital: 491,999,697
Total A Share: 491,999,697
Listed A Share: 491,999,697
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.180
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 3.057
Market Capitalization(RMB) 10.314B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.